ALPHA TEKNOVA, INC. Deferred Revenue
ALPHA TEKNOVA, INC. (TKNO) had Deferred Revenue of $86.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2026-08-06
- 2026-06-30: Deferred Revenue $86.00K.
- 2026-03-31: Deferred Revenue $11.00K.
- 2025-12-31: Deferred Revenue $6.00K.
- 2025-09-30: Deferred Revenue $3.00K.
| Period end | Deferred Revenue |
|---|---|
| 2026-06-30 | $86.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $11.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $6.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $5.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $14.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $30.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $34.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $24.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $30.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $16.00K 10-K · filed 2025-03-07 |
| 2023-09-30 | $24.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $36.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $51.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $198.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | $487.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $941.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.30M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $200.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |